​

Madrigal Pharmaceuticals (MDGL) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

MDGL Stock Forecast

Madrigal Pharmaceuticals (MDGL) stock forecast, based on 19 Wall Street analysts, predicts a 12-month average price target of $532.50, with a high of $590.00 and a low of $420.00. This represents a 22.19% increase from the last price of $435.78.

$200 $280 $360 $440 $520 $600 High: $590 Avg: $532.5 Low: $420 Last Closed Price: $435.78

MDGL Stock Rating

Madrigal Pharmaceuticals stock's rating consensus is Buy, based on 19 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 17 Buy (89.47%), 1 Hold (5.26%), 1 Sell (5.26%), and 0 Strong Sell (0.00%).

Buy
Total 19 0 1 1 17 Strong Sell Sell Hold Buy Strong Buy

MDGL Price Target Upside V Benchmarks

TypeNameUpside
StockMadrigal Pharmaceuticals22.19%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts334
Avg Price Target$570.00$570.00$532.50
Last Closing Price$435.78$435.78$435.78
Upside/Downside30.80%30.80%22.19%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 25391-114
Sep, 252111-115
Aug, 252111-115
Jul, 253101-115
Jun, 253101-115
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 15, 2025Piper Sandler$540.00$437.1023.54%23.92%
Oct 14, 2025Truist Financial$580.00$437.1032.69%33.09%
Oct 10, 2025Jay OlsonOppenheimer$590.00$428.3037.75%35.39%
May 02, 2025Edward NashCanaccord Genuity$420.00$315.4833.13%-3.62%
May 29, 2024Yasmeen RahimiPiper Sandler$336.00$221.7651.52%-22.90%
May 09, 2024Ed AcreH.C. Wainwright$390.00$208.0487.46%-10.51%
Mar 19, 2024Liisa BaykoEvercore ISI$405.00$265.6852.44%-7.06%
Mar 15, 2024Eliana MerleUBS$410.00$270.3751.64%-5.92%
Mar 15, 2024Akash TewariJefferies$400.00$270.3747.95%-8.21%
Mar 15, 2024Ed AcreH.C. Wainwright$425.00$270.3757.19%-2.47%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 15, 2025Piper SandlerOverweightOverweighthold
Oct 10, 2025OppenheimerOutperformOutperformhold
Sep 29, 2025B. RileyBuyBuyhold
Aug 26, 2025Cowen & Co.BuyBuyhold
Aug 12, 2025UBSBuyBuyhold
May 02, 2025UBSBuyBuyhold
Jan 14, 2025H.C. WainwrightBuyBuyhold
Jul 16, 2024JMP SecuritiesOutperformOutperformhold
Jun 28, 2024Cantor FitzgeraldNeutralinitialise
Jun 10, 2024Wolfe ResearchOutperforminitialise

Financial Forecast

EPS Forecast

$-50 $-20 $10 $40 $70 $100 Dec 20 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-12.78$-19.99$-21.90----
Avg Forecast$-12.93$-19.44$-23.62$-12.97$2.87$32.05$57.26
High Forecast$-6.02$-18.30$-22.60$-3.19$9.94$46.90$75.38
Low Forecast$-19.37$-20.11$-24.76$-22.28$-4.22$7.13$34.14
Surprise %-1.16%2.83%-7.28%----

Revenue Forecast

$0 $800M $2B $2B $3B $4B Dec 20 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported--$180.13M----
Avg Forecast$9.18M-$172.04M$514.95M$1.02B$1.88B$2.92B
High Forecast$11.02M-$182.74M$633.56M$1.02B$1.94B$3.64B
Low Forecast$7.34M-$161.27M$412.06M$1.02B$1.82B$2.02B
Surprise %--4.71%----

Net Income Forecast

$-500M $-100M $300M $700M $1B $2B Dec 20 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-197.44M$-373.63M$-465.89M----
Avg Forecast$-172.74M$-373.63M$-442.50M$-297.44M$117.58M$782.67M$1.07B
High Forecast$-138.19M$-342.06M$-422.26M$-59.61M$185.69M$876.45M$1.41B
Low Forecast$-207.29M$-375.85M$-462.74M$-416.30M$-78.80M$133.33M$637.91M
Surprise %14.30%-5.29%----

MDGL Forecast FAQ

Is Madrigal Pharmaceuticals stock a buy?

Madrigal Pharmaceuticals stock has a consensus rating of Buy, based on 19 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 17 Buy, 1 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Madrigal Pharmaceuticals is a favorable investment for most analysts.

What is Madrigal Pharmaceuticals's price target?

Madrigal Pharmaceuticals's price target, set by 19 Wall Street analysts, averages $532.5 over the next 12 months. The price target range spans from $420 at the low end to $590 at the high end, suggesting a potential 22.19% change from the previous closing price of $435.78.

How does Madrigal Pharmaceuticals stock forecast compare to its benchmarks?

Madrigal Pharmaceuticals's stock forecast shows a 22.19% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Madrigal Pharmaceuticals over the past three months?

  • October 2025: 21.43% Strong Buy, 64.29% Buy, 7.14% Hold, 0% Sell, 7.14% Strong Sell.
  • September 2025: 13.33% Strong Buy, 73.33% Buy, 6.67% Hold, 0% Sell, 6.67% Strong Sell.
  • August 2025: 13.33% Strong Buy, 73.33% Buy, 6.67% Hold, 0% Sell, 6.67% Strong Sell.

What is Madrigal Pharmaceuticals’s EPS forecast?

Madrigal Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2025 is $-12.97, marking a -40.78% decrease from the reported $-21.9 in 2024. Estimates for the following years are $2.87 in 2026, $32.05 in 2027, and $57.26 in 2028.

What is Madrigal Pharmaceuticals’s revenue forecast?

Madrigal Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2025 is $514.95M, reflecting a 185.87% increase from the reported $180.13M in 2024. The forecast for 2026 is $1.02B, followed by $1.88B for 2027, and $2.92B for 2028.

What is Madrigal Pharmaceuticals’s net income forecast?

Madrigal Pharmaceuticals's net income forecast for the fiscal year ending in December 2025 stands at $-297M, representing a -36.16% decrease from the reported $-466M in 2024. Projections indicate $117.58M in 2026, $782.67M in 2027, and $1.07B in 2028.